TAE Life Sciences has collaborated with The Ohio State University Comprehensive Cancer Center to advance boron drug innovation for precision cancer therapy.
The partnership aims to develop and evaluate novel boron-based compounds, crucial for Boron Neutron Capture Therapy (BNCT), marking a significant step in precision oncology.
The collaboration is the first US-based academic-industry alliance focused on accelerating BNCT drug innovation and translational research.
TAE Life Sciences and the Ohio State University Comprehensive Cancer Center aim to optimise boron delivery agents.
The organisations will enhance BNCT’s potential as a highly selective and non-toxic therapy, ushering in a new era of precision oncology.
Initially, the collaboration will focus on preclinical evaluation of TAE Life Sciences’ proprietary boron-10 drugs using cellular and animal models.
Ohio State’s specialised neutron source, optimised for BNCT research, will be utilised.
TAE Life Sciences CEO Robert Hill said: “This partnership marks a major leap forward for the future of BNCT. We are deeply honoured to collaborate with Dr. Chakravarti and his world-class team of research and clinical experts.
“Their pioneering track record of leadership and innovation will be instrumental not only in advancing the science behind novel boron drug compounds but also in paving the way toward potential regulatory approval. Together, we’re creating a dynamic force for innovation that has the potential to redefine cancer care.”
Concurrently, the teams will work on developing next-generation boron drugs for BNCT and related applications, advancing precision cancer treatment.
The partnership is seen as a pivotal development for accelerator-based BNCT, potentially accelerating breakthrough cancer therapies.
The collaboration aims to position the US as a leader in precision oncology innovation, supported by international clinical evidence from Europe, Japan, and Taiwan.
It will demonstrate BNCT’s effectiveness in treating otherwise untreatable cancers.
Klotz Family chair of cancer research and professor of radiation oncology Arnab Chakravarti said: “We are entering a pivotal moment in cancer therapy.
“BNCT offers an unprecedented opportunity to treat malignancies that are otherwise unresponsive to conventional therapies, while sparing healthy tissue.
“Our laboratory is uniquely poised to lead this next wave of boron drug innovation, and we are excited to collaborate with TAE Life Sciences in accelerating this effort on a global scale.”
